MorphoSys AG : Article in STAT News again raised concerns that the acquisition might not go through
>Q1 results as a non-event - Sales in Q1 2024 totalled € 27.5m (+13%). Operating expenses rose from € 79.4m in Q1 2023 to as much as € 289.1m. This massive increase in expenses is mainly due to the likely impact of the accelerated vesting of certain share-based payment programmes and the recognition of remuneration-related provisions following the planned acquisition by Novartis. As a result, the operating loss in the first quarter of 2024 amounted to -€ 264m compared...MorphoSys is engaged in development and commercialization of antibodies for therapeutic applications. Co. operates in two segments: Partnered Discovery, which operates therapeutic development programs for drug candidates in cooperation with biotechnology and pharmaceutical companies; and Proprietary Development, which is engaged in the development of therapeutic antibodies in the area of inflammatory disease and oncology on a proprietary basis. As of Dec 31 2013, Co.'s proprietary antibody compounds in clinical trials included MOR103 in the areas of rheumatoid arthritis and multiple sclerosis; MOR202 in the field of multiple myeloma; and MOR208 in the field of malignant B-cell diseases.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.